RA Capital Management, L.P. and related reporting persons filed Amendment No. 5 to a Schedule 13D with the SEC, disclosing the purchase of 8,625,000 shares of PepGen Inc. common stock on November 13, 2026, and reporting aggregate beneficial ownership of 28,742,212 shares, or 30.5% of the class.
Key Highlights
- Shares purchased: RA Capital Healthcare Fund, L.P. acquired 8,625,000 shares of PepGen common stock on November 13, 2026.
- Price per share: The shares were purchased at $5.00 per share from underwriters of the 2026 Public Offering.
- Aggregate purchase price: The Fund paid $43.125 million, funded by its working capital, according to the filing.
- Total beneficial ownership: RA Capital Management and its associated reporting persons report shared beneficial ownership of 28,742,212 shares, representing 30.5% of the class.
- Fund-level holdings: RA Capital Healthcare Fund, L.P. directly holds 27,179,273 shares, equal to 28.8% of the class, the filing states.
- Reporting persons: The filing is made jointly by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.
RA Capital Increases PepGen Stake Through November 2026 Public Offering
According to the Schedule 13D/A filed with the SEC, RA Capital Healthcare Fund, L.P. participated in what the filing describes as the "2026 Public Offering" by PepGen Inc. (NASDAQ:PEPG), purchasing 8,625,000 shares of common stock at $5.00 per share on November 13, 2026. The total consideration paid by the Fund was $43.125 million, sourced from the Fund's working capital. The filing is Amendment No. 5 to a Schedule 13D originally filed on May 20, 2022, and previously amended on June 23, 2022, February 13, 2024, March 11, 2024, and September 30, 2025.
The four reporting persons - RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. - collectively report shared voting and dispositive power over 28,742,212 shares, representing 30.5% of PepGen's outstanding common stock. The filing breaks down the total beneficial ownership as follows: 27,179,273 shares directly held by the Fund; 1,302,600 shares held by RA Capital Nexus Fund II, L.P.; 207,672 shares held through a separately managed account; and 52,667 shares underlying vested stock options held by Dr. Joshua Resnick for the benefit of RA Capital.
The filing notes that the Fund and the Nexus Fund II have each delegated sole voting and dispositive power over their holdings to RA Capital, and "may not revoke that delegation on less than 61 days' notice." RA Capital, Dr. Kolchinsky, and Mr. Shah each disclaim beneficial ownership of the reported securities "other than for the purpose of determining their obligations under Section 13(d) of the Act," according to the filing.
What Was Disclosed
RA Capital Management and affiliated reporting persons amended their Schedule 13D to report the purchase of 8,625,000 PepGen common shares at $5.00 each on November 13, 2026, bringing the group's total reported beneficial ownership to 28,742,212 shares, or 30.5% of the class.



Please wait processing your request...